Diagnostic management of patients with osteoporosis seen in primary health care medical centers in Spain;Manejo diagnóstico de las pacientes con osteoporosis atendidas en consultas de Atención Primaria en España

Semergen

Volumn 33, Issue 2, 2007, Pages 45-49

  Fuentes, M ^a   Ferrer, J ^b   Grifols, M ^c   Badia, X ^d   Guilera Sarda M ^d  

^a Área Básica de Salud Alt Berguedà   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^c Laboratorios Esteve   (Spain)

^d Health Outcomes Research Europe   (Spain)

Author keywords

Diagnosis; Osteoporosis; Risk factors

Indexed keywords

EID: 34547884623     PISSN: 11383593     EISSN: 15788865     Source Type: Journal    
DOI: 10.1016/S1138-3593(07)73849-2     Document Type: Conference Paper

References (17)

1. Osteoporosis postmenopáusica. Guía de práctica clínica. Rev Clin Esp. 2003;203:496-506.
2. Díaz CM, García JJ, Carrasco JL, et al. Prevalencia de osteoporosis determinada por densitometría en la población femenina española. Med Clin (Barc). 2001;116:86-8.
3. Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D. Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int. 1997;7:390-406.
4. Papa LJ, Weber BE. Physician characteristics associated with the use of bone densitometry. J Gen Intern Med. 1997;12:781-83.
5. Summaries for patients. Screening for osteoporosis: recommendations from the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137:I59.
6. López A, Alonso P, Bailón E, et al. Actividades preventivas en el climaterio. Aten Primaria. 2003;32 Supl 2:121-42.
7. Melton LJ, III. Adverse outcomes of osteoporotic fractures in the general population. J Bone Miner Res. 2003;18:1139-41.
8. Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab. 2002;87:3609-17.
9. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995;333:1437-43.
10. González-Macías J, Marín F, Vila J, et al. Prevalencia de factores de riesgo de osteoporosis y fracturas osteoporóticas en una serie de 5.195 mujeres mayores de 65 años. Med Clin (Barc). 2004;123:85-9.
11. Zwart SM, Fradera VM, Solanas SP, et al. Abordaje de la osteoporosis en un centro de atención primaria. Aten Primaria. 2004;33:183-7.
12. Grupo osteoporosis de la semFYC. Osteoporosis. Guía de abordaje. Recomendaciones semFYC. Barcelona: EdiDe; 2000.
13. Aragonés FR, Orozco LP. Abordaje de la osteoporosis en la atención primaria en España (estudio ABOPAP-2000). Aten Primaria. 2002;30:350-6.
14. Simonelli C, Killeen K, Mehle S, et al. Barriers to osteoporosis identification and treatment among primary care physicians and orthopedic surgeons. Mayo Clin Proc. 2002;77:334-8.
15. Suárez-Almazor M, Homik JE, Messina D, et al. Attitudes and beliefs of family physicians and gynecologists in relation to the prevention and treatment of osteoporosis. J Bone Miner Res. 1997;12:1100-7.
16. Richardson JC, Hassell AB, Thomas E, et al. GPs' perceptions of the role of DEXA scanning: an exploratory study. Fam Pract. 2004;21:51-3.
17. Siris ES, Chen YT, Abbott TA, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med. 2004;164:1108-12.